2902 GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation. (September 2015) - Sepúlveda, J.M.; Vaz, M.A.; Gil, M.; Reynés, G.; Gallego, O.; Bolós, M.V.; Laýn, A. Hernádez; Sánchez-Gómez, P.; Martýnez, M.; Vicente, E.; Quindos, M.; Luque, R.; et al.